HomeAI · summaries
Storia in 5 fonti
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder — with the trial meeting its primary and all key secondary efficacy endpoints.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
- ·
zerohedge.com
Psychedelic Stocks Could Explode Higher
Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...
- ·
endpoints.news
Definium reports Phase 3 hit for LSD drug in severe form of depression
Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in depression symptoms.
- ·
benzinga.com
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi
Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with…
- ·
investors.com
Biotech Goes Sky-High After LSD Drug Treats Depression
One analyst called this a "best-case" scenario for the company's experimental depression treatment.
- ·
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.
- ·
Definium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. Announces Proposed Public Offering
- ·
What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.
- ·
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering